Camlin Fine Sciences Limited (CAMLINFINE) — Board Meeting

{ "summary": "Camlin Fine Sciences Limited approved its audited standalone and consolidated financial results for FY 2025-26, reporting a consolidated profit before tax of [amount context mismatch] crores versus a standalone loss of [amount context mismatch] crores. The Board appointed Pankaj Pandey as CFO effective August 18, 2026, and re-designated Santosh Parab as President – Strategy and Global CFO. The Annual General Meeting is scheduled for August 11, 2026. No material changes or forward guidance were disclosed.", "extractedFields": { "keyEvent": "Board approved audited FY26 financials and key appointments", "whatChanged": null, "forwardGuidance": null, "investorTakeaway": "The company posted a consolidated profit but a standalone loss, indicating mixed performance requiring further operational review.", "sentiment": "neutral" }, "companyName": "Camlin Fine Sciences Limited", "exchange": "NSE", "filingDate": "2026-05-26", "filingType": "Announcements", "boardMeetingDate": "2026-05-26", "auditedFinancials": { "yearEnded": "2026-03-31", "auditedStandalone": true, "auditedConsolidated": true, "auditorOpinion": "unmodified" }, "appointments": { "costAuditor": "M/s. ABK & Associates, Cost Accountants", "internalAuditor": "M/s. Mahajan & Aibara, Chartered Accountants", "cfoAppointment": { "name": "Mr. Pankaj Pandey", "effectiveDate": "2026-08-18", "role": "Chief Financial Officer (CFO) and Key Managerial Personnel" }, "cfoReDesignation": { "name": "Mr. Santosh Parab", "newRole": "President – Strategy and Global CFO" } }, "agm": { "date": "2026-08-11", "time": "10:00 a.m.", "mode": "permissible mode" }, "regulatoryDisclosures": [ "Regulation 30 & 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015", "Annexure 1: Audited Financial Results and Auditor's Reports", "Annexure 2: Disclosures under Regulation 30 read with Schedule III" ], "equitySharesIssued": 4106181, "faceValuePerShare": 1, "securitiesPremiumPerShare": 246.69, "investmentInVmpaiEUR": 3300000, "convertibleBondsIssued": 3300, "bondConversionPricePerBond": 1000, "newSharesFromBondConversion": 1100000, "acquisitionStakePercentage": 83.82, "goodwillRecorded": 16810.5, "escrowTransferAmountEUR": 2560907, "escrowTransferAmountINR": 279177, "auditOpinion": "Unmodified opinion on consolidated financial results", "auditPeriod": "Year ended March 31, 2026", "regulatoryFramework": [ "SEBI LODR Regulations 2015", "Indian Accounting Standards (Ind AS)" ], "auditScope": { "entitiesAudited": 24, "subsidiariesIncluded": [ "Chemolutions Chemicals Ltd. (Subsidiary)", "Alga!R Nutra Pharms Private Limited (Subsidiary)", "CFS North America LLC (Wholly owned subsidiary)", "CFS Do Brasil Industria, Comercio, Importacao e Exportacao De Aditivos Alimentfcios L TDA (Wholly owned subsidiary)", "Solentus North America Inc (Wholly owned subsidiary)", "CFS Europe S.P.A (Under liquidation from March 17, 2026) (Wholly owned subsidiary)", "Dresen Quimica S.A.P.l de C.V. (Wholly owned subsidiary)", "Industrias Petrotec De Mexico S.A. de C.V. (Step down subsidiary)", "Nuvel, S.A.C. (Step down subsidiary)", "Britec, S.A. (Step down subsidiary)", "Inovel, S.A.S (Step down subsidiary)", "Grine!, S.R.L (Step down subsidiary)", "CFS Wanglong Flavors (Ningbo) Co. Ltd. (Subsidiary)", "CFS Pahang Asia Pte. Ltd (Subsidiary, struck off November 4, 2025)" ], "associatesIncluded": [ "CFS Europe S.P.A (Under liquidation from March 17, 2026) (Step down subsidiary)" ], "associateNetProfitBeforeAdjustments_FY_2026": 138.29, "associateTotalComprehensiveIncomeBeforeAdjustments_FY_2026": 166.21 }, "boardMeetingOutcome": "Approved audited standalone and consolidated financial results for FY 2025-26", "auditedStandaloneTotalIncome": 56921.10, "auditedConsolidatedTotalIncome": 123433.00, "auditedStandaloneProfitBeforeTax": -5409.22, "auditedConsolidatedProfitBeforeTax": 6457.67, "netCashFlowFromOperatingActivitiesStandalone": 4395.98, "netCashFlowFromOperatingActivitiesConsolidated": 8206.86, "netCashFlowUsedInInvestingActivitiesStandalone": -3039.57, "netCashFlowUsedInInvestingActivitiesConsolidated": -5295.18, "netCashFlowFromFinancingActivitiesStandalone": -1341.11, "netCashFlowFromFinancingActivitiesConsolidated": -2463.23, "cashAndCashEquivalentsEndOfYearStandalone": 3621.85, "cashAndCashEquivalentsEndOfYear